Drugs / Quilizumab
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT01160861 | Jul 2010 → Apr 2011 | allergic rhinitis | Genentech, Inc. | Completed | No outcome recorded |
| Phase 22 trials · 1 missed | ||||||
| Phase 2 | NCT01582503 | Apr 2012 → May 2014 | asthma | Genentech, Inc. | Completed | Missed primary |
| Phase 2 | NCT01196039 | Dec 2010 → Aug 2011 | asthma | Genentech, Inc. | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT01987947 Comparator | Dec 2013 → Oct 2014 | urticaria | Genentech, Inc. | Completed | No outcome recorded |
Evidence & citations 10 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Quilizumab | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01987947 ↗ |
| Known as | ANTI-M1 | ChEMBL registry synonym — accepted as the source's own label CHEMBL2109456 ↗ |
| Known as | Anti-M1 prime | ChEMBL registry synonym — accepted as the source's own label CHEMBL2109456 ↗ |
| Known as | MEMP1972A | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01582503 ↗ |
| Known as | MEP-1972A | ChEMBL registry synonym — accepted as the source's own label CHEMBL2109456 ↗ |
| Known as | RG-7449 | ChEMBL registry synonym — accepted as the source's own label CHEMBL2109456 ↗ |
| Action | Inhibit | “Ig epsilon chain C region inhibitor” CHEMBL2109456 ↗ |
| Modality | Monoclonal antibody | — CHEMBL2109456 ↗ |
| Route | Subcutaneous | “Two administrations by subcutaneous injection” NCT01987947 ↗ |
| Target | IGHE | “Ig epsilon chain C region inhibitor” CHEMBL2109456 ↗ |